However, other measures remained unchanged
Oh, and heres a little nugget: the dosage can vary between the genders
These benefits occur quickly following treatment initiation, suggesting that GLP-1 medicines may reduce cardiovascular events, at least in part, through weight loss-independent mechanisms
Seiwerth S, Brcic L, Vuletic LB, Kolenc D, Aralica G, Misic M, et al
GLP-1 Timeline: From Diabetes to Pediatric Weight Management 2005: First GLP-1 medications approved for Type 2 diabetes in adults 2014: FDA approves Saxenda (liraglutide) as the first GLP-1 for weight loss 2022: Wegovy approved for adolescents 12 and older 2023: American Academy of Pediatrics endorses GLP-1s for pediatric obesity 2025: FDA considering approval for children as young as 6 years old Though the FDA approved Saxenda as the first GLP-1 for weight loss back in 2014, it wasnt until the last few years that the popularity and availability of these medications for obesity have skyrocketed